Unveiling immune cell response disparities in human primary cancer-associated fibroblasts between two- and three-dimensional cultures
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0314227 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Jian-Ping Yang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Takeda Development Center Americas, Inc., San Diego, California, United States of America. Hauptthemen laut MEDLINE: Cancer-Associated Fibroblasts, Tumor Microenvironment, Killer Cells, Natural. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cancer-associated fibroblasts (CAFs) play pivotal roles in solid tumor initiation, growth, and immune evasion. However, the optimal biomimetic modeling conditions remain elusive. In this study, we investigated the effects of 2D and 3D culturing conditions on human primary CAFs integrated into a modular tumor microenvironment (TME). Using single-nucleus RNA sequencing (snRNAseq) and Proteomics’ Proximity Extension Assays, we characterized CAF transcriptomic profiles and cytokine levels. Remarkably, when cultured in 2D, CAFs exhibited a myofibroblast (myCAF) subtype, whereas in 3D tumor spheroid cultures, CAFs displayed a more inflammatory (iCAF) pathological state. By integrating single-cell gene expression data with functional interrogations of critical TME-related processes [natural killer (NK)-mediated tumor killing, monocyte migration, and macrophage differentiation], we were able to reconcile form with function. In 3D TME spheroid models, CAFs enhance cancer cell growth and immunologically shield cells from NK cell-mediated cytotoxicity, in striking contrast with their 2D TME counterparts. Notably, 3D CAF-secreted proteins manifest a more immunosuppressive profile by enhancing monocyte transendothelial migration and differentiation into M2-like tumor-associated macrophages (TAMs). Our findings reveal a more immunosuppressive and clinically relevant desmoplastic TME model that can be employed in industrial drug discovery campaigns to expand the cellular target range of chemotherapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Takeda Development Center Americas, Inc., San Diego, California, United States of America.
- Takeda Pharmaceutical Company Ltd, Fujisawa, Kanagawa, Japan.
- BioTuring, San Diego, California, United States of America.
- Bristol-Myers Squibb, Princeton, New Jersey, United States of America.
- Takeda Development Center Americas, Inc., Cambridge, Massachusetts, United States of America.
ORCID-Profile: Jian-Ping Yang, Masashi Yamaji, Tsubasa Shiraishi
Zitieren
APA
Yang, J. P., Kulkarni, N. N., Yamaji, M., Shiraishi, T., Pham, T., Do, H., Aiello, N., Shaw, M., Nakamura, T., Abiru, A., Gavva, N. R., & Horman, S. R. (2024). Unveiling immune cell response disparities in human primary cancer-associated fibroblasts between two- and three-dimensional cultures. PLOS ONE. https://doi.org/10.1371/journal.pone.0314227
Vancouver
Yang JP, Kulkarni NN, Yamaji M, Shiraishi T, Pham T, Do H, et al. Unveiling immune cell response disparities in human primary cancer-associated fibroblasts between two- and three-dimensional cultures. PLOS ONE. 2024. doi:10.1371/journal.pone.0314227
BibTeX
@article{Yang2024,
author = {Yang, Jian-Ping and Kulkarni, Nikhil Nitin and Yamaji, Masashi and Shiraishi, Tsubasa and Pham, Thang and Do, Han and Aiello, Nicole and Shaw, Michael and Nakamura, Toshihiro and Abiru, Akiko and Gavva, Narender R and Horman, Shane R},
title = {Unveiling immune cell response disparities in human primary cancer-associated fibroblasts between two- and three-dimensional cultures},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0314227}
}
EUVIMED